iCure Receives FDA Approval for Phase 1 Clinical Trial Plan of Donepezil Patch in the US
[Asia Economy Reporter Minji Lee] iQure announced on the 30th that it has received approval from the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial plan of a donepezil patch indicated for Alzheimer's disease.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- 'Still Hesitant? If You're Wondering Whether KOSPI Will Rise, This Is the Number You Must Watch [Weekend Money]'
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Fire Breaks Out on 29th Floor of Tower Palace in Seoul; About 40 Residents Evacuated, No Injuries Reported
- Is It Really Like an Illness? "I Can't Wait to Go Again"—Over 1 Million Visited in Q1, Now 'Busanbyeong' Takes Hold [K-Holic]
The company stated, "It will be able to provide a better method of administration compared to oral donepezil, which is currently used as a treatment for Alzheimer's disease."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
